Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Feb 2;58(5):1126–1132. doi: 10.2337/db08-1595

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 1. — Norepinephrine kinetics in response to 75 g oral glucose at baseline and after weight loss (WL) (n = 34): whole-body norepinephrine plasma spillover rate (A), arterial norepinephrine concentration (B), and norepinephrine plasma clearance (C). Values are means ± SE. Data (log transformed) were analyzed by two-way repeated-measures ANOVA, using the Holm-Sidak test for pairwise comparisons. **P < 0.01 and ***P < 0.001 versus time 0. Whole-body norepinephrine spillover rate: time effect P < 0.001; treatment effect P = 0.01; time × treatment interaction P = 0.003. Arterial norepinephrine concentration: time effect P < 0.001; treatment effect P < 0.001; time × treatment interaction P = 0.07. Norepinephrine plasma clearance: no significant time, treatment, or interaction effects. ●, baseline; ○, post–weight loss.